Consequently, single-gene tests are usually applied only to those malignancies, where the probability of detecting corresponding targetable alteration is at least 2–5%; for example, EGFR testing is a standard diagnostic procedure for non-small cell lung cancer, but is actually never used for other tumor entities. Here, EGFR is linked to non-small cell lung carcinoma.